For other put options contract ideas at the various different available expirations, visit the ATHX Stock Options page of StockOptionsChannel.com. In mid-afternoon trading on Friday, the put volume among S&P 500 components was …
The United Kingdom-based Oxford Asset Management has invested 0.01% in the stock. Prudential Plc, a Illinois-based fund reported 2.15 million shares. Analysts await Athersys, Inc. (NASDAQ:ATHX) to report earnings on May, 9 after …
Genetics
Athersys Inc. (ATHX) plans to sell more than 19.8 million common shares ... The news of the offering at a steep discounted price crushed the company's stock price on Friday, which closed at $1.12 per share, down 27% from the …
Athersys, Inc. (NASDAQ:ATHX) investors cheer the announcement that the stem cell company received Special Protocol Assessment (SPA) from the FDA for the design and planned analysis of a Phase 3 clinical trial of Athersys’ novel …
Athersys, Inc. (NASDAQ: ATHX) 22.4% LOWER; intends to offer for sale shares of its common stock, par value $0.001 …
Athersys, Inc. (ATHX) will report its next earnings on Mar 09 AMC ... Inc. and for the current quarter 3 analysts have projected that the stock could give an Average Earnings estimate of $-0.07/share. These analysts have also projected a …
ATHX 3.00 Athersys $ATHX stock added to my watch list. Right now with ATHX I am watching the last price 3.00 High 3.00 Low 3.00 Change +0.03 and percent change +1.01% Do you have any opinions about ATHX? Share them with …
Here are 5 stocks added to the Zacks #5 Rank ("strong sell") List today: View the entire Zacks #5 Rank List. ATHERSYS INC (ATHX): Free Stock Analysis Report BANK OF AMERICA CORPORATION (BAC): Free Stock Analysis Report …
The stock’s market capitalization is 100.03M, it has a 52-week low of 1.02 and a 52-week high of 2.90. The share price of the company (ATHX) was down -0.85%, with a high of 1.20 during the day and the volume of Athersys, Inc. shares …
Athersys Inc. (ATHX) suffered a blow on Friday with the stock price dropping to a new 52-week low, on news that the primary and secondary endpoints of the company's phase II study of MultiStem cell therapy for treatment of ischemic …